Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Pharmacol. 2007 Oct;7(5):455-8. Epub 2007 Jul 23.

    Clostridium difficile: new therapeutic options.

    Source

    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street, Room 439, Baltimore, MD 21287, USA. abalago1@jhmi.edu

    Abstract

    Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.

    PMID:
    17644040
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk